# NanoRibo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanoribo

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.nanoribo.com
- Latest round: Series A (Feb 10, 2025)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2021, NanoRibo (Shanghai) Biotechnology Co., Ltd, dba NanoRibo, focuses on innovative RNA therapeutics aimed at enhancing immune responses against cancers. The firm specializes in advanced immunotherapy solutions that leverage RNA-based technologies to enhance therapeutic efficacy in cancer treatment. The company's core product offerings focus on novel RNA therapeutics aimed at modulating immune responses to target malignancies more effectively. These innovative therapies are designed to activate the immune system, recognizing and destroying cancer cells while sparing healthy tissue. The revenue structure of NanoRibo is primarily founded on B2B partnerships with healthcare providers and research institutions, facilitating the distribution and application of its RNA-based therapies. Transactions typically involve direct sales agreements, where healthcare facilities purchase therapeutic products for clinical use. 
In January 2026, Chengdu Kanghua Biological Products Co.,Ltd., a portfolio company of Yingke Private Equity, agreed to fully acquire NanoRibo.

## Funding rounds

- Series A, Feb 10, 2025 — Ennovation Ventures, BIO-TOWN Capital

## Investors

- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series A